Editas Operating Income from 2010 to 2025

EDIT Stock

USD 1.30 0.09 6.47%

Editas Medicine Operating Income yearly trend continues to be comparatively stable with very little volatility. Operating Income is likely to outpace its year average in 2025. Operating Income is earnings before interest and taxes (EBIT), representing the amount of profit Editas Medicine generates from its operations. View All Fundamentals

Operating Income

First Reported

2014-12-31

Previous Quarter

-65.7 M

Current Value

-46.6 M

Quarterly Volatility

19.3 M

Yuan Drop

Covid

Check Editas Medicine financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Editas Medicine's main balance sheet or income statement drivers, such as Depreciation And Amortization of 3.5 M, Interest Expense of 3 M or Selling General Administrative of 59.8 M, as well as many indicators such as Price To Sales Ratio of 3.07, Dividend Yield of 0.0 or PTB Ratio of 0.61. Editas financial statements analysis is a perfect complement when working with Editas Medicine Valuation or Volatility modules.

Check out the analysis of Editas Medicine Correlation against competitors.

For more information on how to buy Editas Stock please use our How to Invest in Editas Medicine guide.

Latest Editas Medicine's Operating Income Growth Pattern

Below is the plot of the Operating Income of Editas Medicine over the last few years. Operating Income is the amount of profit realized from Editas Medicine operations after accounting for operating expenses such as cost of goods sold (COGS), wages and depreciation. Operating income takes the gross income and subtracts other operating expenses and then removes depreciation. Operating Income of Editas Medicine is typically a synonym for earnings before interest and taxes (EBIT) and is also commonly referred to as operating profit or recurring profit. It is earnings before interest and taxes (EBIT), representing the amount of profit a company generates from its operations. Editas Medicine's Operating Income historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Editas Medicine's overall financial position and show how it may be relating to other accounts over time.

Operating Income

10 Years Trend

Slightly volatile

Compare to Others All Fundamentals

Operating Income

Timeline

Editas Operating Income Regression Statistics

	Arithmetic Mean	(111,472,525)
	Geometric Mean	66,049,656
	Coefficient Of Variation	(78.56)
	Mean Deviation	73,024,084
	Median	(113,727,000)
	Standard Deviation	87,570,175
	Sample Variance	7668.5T
	Range	238.4M
	R-Value	(0.96)
	Mean Square Error	636.5T
	R-Squared	0.92
	Slope	(17,666,656)
	Total Sum of Squares	115028T

Editas Operating Income History

	2025	-238.6 M
	2024	-251.2 M
	2023	-169.2 M
	2022	-225.9 M
	2021	-193.1 M
	2020	-134.8 M
	2019	-140.9 M

Other Fundumenentals of Editas Medicine

Non Operating Income Net Other

Editas Medicine Operating Income component correlations

	Total Assets	Total Stockholder Equity	Net Debt	Retained Earnings	Accounts Payable	Total Liab	Total Current Assets	Property Plant Equipment	Net Tangible Assets	Current Deferred Revenue	Long Term Debt	Net Receivables	Deferred Long Term Liab	Short Long Term Debt	Short Term Debt	Common Stock	Short Term Investments	Capital Surpluse	Long Term Debt Total	Net Invested Capital	Net Working Capital	Long Term Investments	Capital Stock
Total Assets		0.95	-0.82	-0.72	0.86	0.73	0.99	0.6	0.93	0.62	0.83	0.3	0.91	0.74	0.84	0.66	0.96	0.86	-0.6	0.63	0.49	0.69	0.52
Total Stockholder Equity	0.95		-0.8	-0.66	0.81	0.47	0.9	0.49	0.93	0.57	0.64	0.22	0.8	0.54	0.8	0.63	0.93	0.83	-0.51	0.76	0.56	0.8	0.5
Net Debt	-0.82	-0.8		0.53	-0.71	-0.53	-0.84	-0.81	-0.8	-0.84	-0.66	-0.14	-0.74	-0.59	-0.53	-0.44	-0.76	-0.67	0.49	-0.41	-0.5	-0.36	-0.31
Retained Earnings	-0.72	-0.66	0.53		-0.79	-0.58	-0.68	-0.31	-0.82	-0.18	-0.65	-0.84	-0.85	-0.58	-0.82	-0.93	-0.7	-0.92	0.89	-0.19	0.12	-0.46	-0.92
Accounts Payable	0.86	0.81	-0.71	-0.79		0.65	0.82	0.56	0.83	0.54	0.77	0.45	0.84	0.69	0.87	0.73	0.79	0.87	-0.59	0.42	0.13	0.62	0.62
Total Liab	0.73	0.47	-0.53	-0.58	0.65		0.8	0.61	0.56	0.49	0.91	0.34	0.8	0.88	0.62	0.48	0.66	0.6	-0.56	0.12	0.15	0.19	0.38
Total Current Assets	0.99	0.9	-0.84	-0.68	0.82	0.8		0.69	0.89	0.66	0.86	0.26	0.92	0.77	0.78	0.6	0.95	0.81	-0.61	0.54	0.5	0.57	0.46
Property Plant Equipment	0.6	0.49	-0.81	-0.31	0.56	0.61	0.69		0.48	0.83	0.71	0.02	0.64	0.68	0.37	0.14	0.55	0.38	-0.37	0.01	0.23	-0.04	0.04
Net Tangible Assets	0.93	0.93	-0.8	-0.82	0.83	0.56	0.89	0.48		0.51	0.71	0.44	0.88	0.61	0.83	0.83	0.9	0.95	-0.66	0.6	0.35	0.7	0.72
Current Deferred Revenue	0.62	0.57	-0.84	-0.18	0.54	0.49	0.66	0.83	0.51		0.62	-0.12	0.49	0.6	0.32	0.09	0.52	0.35	-0.16	0.28	0.45	0.22	-0.05
Long Term Debt	0.83	0.64	-0.66	-0.65	0.77	0.91	0.86	0.71	0.71	0.62		0.34	0.83	0.98	0.8	0.57	0.69	0.72	-0.55	0.27	0.16	0.36	0.48
Net Receivables	0.3	0.22	-0.14	-0.84	0.45	0.34	0.26	0.02	0.44	-0.12	0.34		0.55	0.31	0.48	0.75	0.3	0.6	-0.85	-0.24	-0.52	0.11	0.84
Deferred Long Term Liab	0.91	0.8	-0.74	-0.85	0.84	0.8	0.92	0.64	0.88	0.49	0.83	0.55		0.74	0.79	0.73	0.92	0.87	-0.82	0.29	0.18	0.43	0.64
Short Long Term Debt	0.74	0.54	-0.59	-0.58	0.69	0.88	0.77	0.68	0.61	0.6	0.98	0.31	0.74		0.75	0.48	0.58	0.61	-0.49	0.2	0.12	0.28	0.41
Short Term Debt	0.84	0.8	-0.53	-0.82	0.87	0.62	0.78	0.37	0.83	0.32	0.8	0.48	0.79	0.75		0.8	0.74	0.88	-0.58	0.54	0.13	0.72	0.73
Common Stock	0.66	0.63	-0.44	-0.93	0.73	0.48	0.6	0.14	0.83	0.09	0.57	0.75	0.73	0.48	0.8		0.63	0.94	-0.72	0.32	-0.09	0.56	0.97
Short Term Investments	0.96	0.93	-0.76	-0.7	0.79	0.66	0.95	0.55	0.9	0.52	0.69	0.3	0.92	0.58	0.74	0.63		0.82	-0.65	0.58	0.5	0.63	0.48
Capital Surpluse	0.86	0.83	-0.67	-0.92	0.87	0.6	0.81	0.38	0.95	0.35	0.72	0.6	0.87	0.61	0.88	0.94	0.82		-0.71	0.47	0.13	0.66	0.86
Long Term Debt Total	-0.6	-0.51	0.49	0.89	-0.59	-0.56	-0.61	-0.37	-0.66	-0.16	-0.55	-0.85	-0.82	-0.49	-0.58	-0.72	-0.65	-0.71		0.07	0.13	-0.15	-0.74
Net Invested Capital	0.63	0.76	-0.41	-0.19	0.42	0.12	0.54	0.01	0.6	0.28	0.27	-0.24	0.29	0.2	0.54	0.32	0.58	0.47	0.07		0.76	0.9	0.18
Net Working Capital	0.49	0.56	-0.5	0.12	0.13	0.15	0.5	0.23	0.35	0.45	0.16	-0.52	0.18	0.12	0.13	-0.09	0.5	0.13	0.13	0.76		0.46	-0.26
Long Term Investments	0.69	0.8	-0.36	-0.46	0.62	0.19	0.57	-0.04	0.7	0.22	0.36	0.11	0.43	0.28	0.72	0.56	0.63	0.66	-0.15	0.9	0.46		0.45
Capital Stock	0.52	0.5	-0.31	-0.92	0.62	0.38	0.46	0.04	0.72	-0.05	0.48	0.84	0.64	0.41	0.73	0.97	0.48	0.86	-0.74	0.18	-0.26	0.45

Click cells to compare fundamentals

About Editas Medicine Financial Statements

Editas Medicine shareholders use historical fundamental indicators, such as Operating Income, to determine how well the company is positioned to perform in the future. Although Editas Medicine investors may analyze each financial statement separately, they are all interrelated. The changes in Editas Medicine's assets and liabilities, for example, are also reflected in the revenues and expenses on on Editas Medicine's income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.

	Last Reported	Projected for Next Year
Operating Income	-251.2 M	-238.6 M
Non Operating Income Net Other	6.3 M	5.6 M

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for Editas Stock Analysis

When running Editas Medicine's price analysis, check to measure Editas Medicine's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Editas Medicine is operating at the current time. Most of Editas Medicine's value examination focuses on studying past and present price action to predict the probability of Editas Medicine's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Editas Medicine's price. Additionally, you may evaluate how the addition of Editas Medicine to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Editas Operating Income from 2010 to 2025

Latest Editas Medicine's Operating Income Growth Pattern

Editas Operating Income Regression Statistics

Editas Operating Income History

Other Fundumenentals of Editas Medicine

Editas Medicine Operating Income component correlations

About Editas Medicine Financial Statements

Thematic Opportunities

Explore Investment Opportunities

Additional Tools for Editas Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY